[go: up one dir, main page]

PE20011180A1 - Vacuna contra la salmonella materiales y metodos - Google Patents

Vacuna contra la salmonella materiales y metodos

Info

Publication number
PE20011180A1
PE20011180A1 PE2001000253A PE2001000253A PE20011180A1 PE 20011180 A1 PE20011180 A1 PE 20011180A1 PE 2001000253 A PE2001000253 A PE 2001000253A PE 2001000253 A PE2001000253 A PE 2001000253A PE 20011180 A1 PE20011180 A1 PE 20011180A1
Authority
PE
Peru
Prior art keywords
nucleotides
salmonella
sequences
ssat
region
Prior art date
Application number
PE2001000253A
Other languages
English (en)
Inventor
David E Lowery
Michael J Kennedy
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20011180A1 publication Critical patent/PE20011180A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA VACUNA QUE CONTIENE UNA CANTIDAD INMUNOLOGICAMENTE PROTECTORA DE SALMONELLA MUTANTE INCAPAZ DE REVERTIR, EN LA QUE SE HA INACTIVADO DOS O MAS GENES DENTRO DE LA REGION ISLA DE PATOGENICIDAD 2 EN SALMONELLA (IP2S); POR SUPRESION DE UNA PORCION DE LA REGION CODIFICANTE DEL GEN DEL APARATO DEL SISTEMA DE SECRECION SSA SELECCIONANDOSE DE SSAT QUE PRESENTA 779 NUCLEOTIDOS, SSAJ DE 749 NUCLEOTIDOS, SSAC DE 1052 NUCLEOTIDOS, SSAM DE 368 NUCLEOTIDOS O EL TRAMO COMPLETO DE LAS SECUENCIAS DE NUCLEOTIDOS QUE SE HIBRIDIZA CON EL COMPLEMENTO NO CODIFICANTE DE LA SECUENCIA DE DICHAS SECUENCIAS DE NUCLEOTIDOS, EN CONDICIONES RIGUROSAS, O UN TRAMO COMPLETO DE LAS SECUENCIAS DE NUCLEOTIDOS DE SALMONELLA QUE POSEE 95% DE IDENTIDAD DE LAS SECUENCIAS DE SSAT, SSAJ, SSAC, SSAM; O MEDIANTE MUTACION POR INSERCION. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UNA SEGUNDA SALMONELLA MUTANTE ATENUADA EN LA QUE SE HAN INACTIVADO UNO O MAS GENES DENTRO DE LA REGION IP2S; QUE SE CARACTERIZAN POR PERTENECER A SEROTIPOS DIFERENTES COMO SALMONELLA ENTERICA, S. DUBLIN, S.TYPHIMURIUM SUBESPECIE ENTERICA O CUALQUIERA DE LOS SIGUIENTES SEROGRUPOS A, B, C1, C2, D1, E1
PE2001000253A 2000-03-17 2001-03-16 Vacuna contra la salmonella materiales y metodos PE20011180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19017800P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
PE20011180A1 true PE20011180A1 (es) 2001-11-15

Family

ID=22700305

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000253A PE20011180A1 (es) 2000-03-17 2001-03-16 Vacuna contra la salmonella materiales y metodos

Country Status (17)

Country Link
US (2) US6923957B2 (es)
EP (1) EP1267899B1 (es)
JP (1) JP2003527433A (es)
AR (1) AR027680A1 (es)
AT (1) ATE300949T1 (es)
AU (2) AU5695701A (es)
BR (1) BR0109322A (es)
CA (1) CA2402252A1 (es)
DE (1) DE60112413T2 (es)
DK (1) DK1267899T3 (es)
ES (1) ES2244617T3 (es)
MX (1) MXPA02008748A (es)
NZ (1) NZ521425A (es)
PE (1) PE20011180A1 (es)
PT (1) PT1267899E (es)
WO (1) WO2001070247A2 (es)
ZA (1) ZA200207002B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521425A (en) * 2000-03-17 2004-05-28 Upjohn Co Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
EP1594560A4 (en) * 2003-01-09 2007-06-06 Univ Pennsylvania COMPOSITIONS, METHODS AND KITS FOR INCREASING THE IMMUNOGENICITY OF A BACTERIA VACCINE VECTOR
CN1297315C (zh) * 2004-11-25 2007-01-31 上海交通大学 抗仔猪细菌性疫病复合卵黄抗体制剂的制备方法
ATE545701T1 (de) * 2005-05-17 2012-03-15 Ozgene Pty Ltd Sequentielles klonierungssystem
US20070191736A1 (en) * 2005-10-04 2007-08-16 Don Alden Method for loading penetrating members in a collection device
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
UA100370C2 (uk) * 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
US7935355B2 (en) * 2007-04-19 2011-05-03 Nutritional Health Institute Laboratories, Llc Composition and method for controlling intestinal pathogenic organisms
US20080260777A1 (en) * 2007-04-19 2008-10-23 Sotomayor Konky Composition and method for controlling intestinal pathogenic organisms
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
AU2008318357B2 (en) 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials
AU2011207331C1 (en) 2010-01-21 2016-05-12 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
CN102971008B (zh) 2010-06-09 2015-11-25 阿肯色大学评议会 降低弯曲菌属感染的疫苗和方法
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
US20150238590A1 (en) * 2012-10-22 2015-08-27 The Board Of Regents For Oklahoma State University Use of the salmonella spp type iii secretion proteins as a protective vaccination
US9950053B2 (en) 2012-10-22 2018-04-24 The Board Of Regents For Oklahoma State University Use of the Salmonella SPP type III secretion proteins as a protective vaccination
WO2014127185A1 (en) 2013-02-14 2014-08-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
CA2967590A1 (en) * 2014-11-11 2016-05-19 Ohio State Innovation Foundation Probiotic bacteria for the prevention and treatment of salmonella
MX2018003173A (es) * 2015-09-16 2018-05-17 Boehringer Ingelheim Vetmedica Inc Vacunas de salmonella choleraesuis-salmonella typhimurium.
MX2018013331A (es) 2016-05-03 2019-06-10 Univ Arkansas Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
US6936425B1 (en) * 1998-09-04 2005-08-30 Microscience Limited Attenuated salmonella SP12 mutants as antigen carriers
NZ519477A (en) 1999-12-23 2004-04-30 Microscience Ltd Attenuated microorganisms for the treatment of infection
NZ521425A (en) * 2000-03-17 2004-05-28 Upjohn Co Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated

Also Published As

Publication number Publication date
ES2244617T3 (es) 2005-12-16
CA2402252A1 (en) 2001-09-27
ZA200207002B (en) 2004-03-31
BR0109322A (pt) 2002-12-10
EP1267899A2 (en) 2003-01-02
EP1267899B1 (en) 2005-08-03
DE60112413T2 (de) 2006-06-01
DK1267899T3 (da) 2005-12-12
WO2001070247A3 (en) 2002-04-18
AU5695701A (en) 2001-10-03
PT1267899E (pt) 2005-11-30
US6923957B2 (en) 2005-08-02
AU2001256957B2 (en) 2005-08-25
WO2001070247A2 (en) 2001-09-27
DE60112413D1 (de) 2005-09-08
AR027680A1 (es) 2003-04-09
JP2003527433A (ja) 2003-09-16
US20050260223A1 (en) 2005-11-24
US20040009191A1 (en) 2004-01-15
MXPA02008748A (es) 2003-02-24
ATE300949T1 (de) 2005-08-15
NZ521425A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
PE20011180A1 (es) Vacuna contra la salmonella materiales y metodos
Mulder et al. Identification of additional virulence determinants on the pYV plasmid of Yersinia enterocolitica W227
AR048596A1 (es) Atenuacion sinergica del virus de estomatitis vesiculosa, sus vectores y sus composiciones inmunogenas
ES2181306T3 (es) Vacunas recombinantes que comprenden bacterias atenuadas inmunogenicas que tienen fenotipo rpos positivo.
PT672116E (pt) Mutantes por supressao como vacinas contra a colera
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
CL2008003202A1 (es) Composicion inmunogenica que comprende bacterias vivas de mycoplasma bovis atenuada avirulenta.
Iskra-Caruana et al. The common evolutionary history of badnaviruses and banana
AR009947A1 (es) COMPOSICIoN DE VACUNA PARA EQUIDOS QUE COMPRENDEN TAMBIEN UN VEHíCULO DE VACUNACIoN.
BR0010418A (pt) Microorganismos atenuados para o tratamento de infecção
Sabaneyeva et al. Host and symbiont intraspecific variability: The case of Paramecium calkinsi and “Candidatus Trichorickettsia mobilis”
Raviv et al. Strain differentiating real-time PCR for Mycoplasma gallisepticum live vaccine evaluation studies
Pereira et al. Molecular characterization of feline calicivirus variants from multicat household and public animal shelter in Rio de Janeiro, Brazil
CL2023001826A1 (es) Eliminación genómica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables
Pánek et al. Creneis carolina gen. et sp. nov.(Heterolobosea), a novel marine anaerobic protist with strikingly derived morphology and life cycle
Damé-Teixeira et al. Genotypic diversity and virulence traits of Streptococcus mutans isolated from carious dentin after partial caries removal and sealing
Aboudharam et al. Detection of Coxiella burnetii DNA in dental pulp during experimental bacteremia
Norris et al. Expression and transcriptional control of the Salmonella typhimurium lpf fimbrial operon by phase variation
HUP0303878A2 (hu) Himlő elleni vakcina
Bertone et al. Genetic-relatedness of peri-implants and buccal Candida albicans isolates determined by RAPD-PCR
Sánchez-Jiménez et al. Distribution of pathogenicity islands among Colombian isolates of Salmonella
MX2023008932A (es) Virus atenuado de la peste porcina africana y su uso como vacuna.
ES2120989T3 (es) Vector virico recombinante de tipo varicela-zoster.
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
KR930013104A (ko) 세르풀리나 하이오다이센테리애 백신

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed